ARTICLE | Financial News
Regeneron up after reporting preliminary Eylea sales
January 15, 2014 2:03 AM UTC
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) gained $31.64 (12%) to $300.32 on Tuesday after announcing preliminary 4Q13 and 2013 U.S. net sales for ophthalmic drug Eylea aflibercept. The company said...